As the battle to buy Pfizer’s $20 billion consumer business heats up, Lysol-owner Reckitt Benckiser is trying to convince investors that its acquisition record is clean. The U.K.-based consumer group is one of two companies to have submitted a nonbinding bid for Advil and other Pfizer brands, according to Reuters and Bloomberg reports this month (the other being healthcare giant GlaxoSmithKline). Discussing Reckitt’s 2017 results Monday, Chief Executive Rakesh Kapoor batted off questions about Pfizer, but delivered a scripted...

Source: Wall Street Journal February 19, 2018 15:11 UTC